Servei de Pneumologia, Institut del Torax, Hospital Clinic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.
Crit Care Med. 2013 Sep;41(9):2133-43. doi: 10.1097/CCM.0b013e31828a453b.
The impact of ICU-acquired pneumonia without etiologic diagnosis on patients' outcomes is largely unknown. We compared the clinical characteristics, inflammatory response, and outcomes between patients with and without microbiologically confirmed ICU-acquired pneumonia.
Prospective observational study.
ICUs of a university teaching hospital.
We prospectively collected 270 consecutive patients with ICU-acquired pneumonia. Patients were clustered according to positive or negative microbiologic results.
None.
We compared the characteristics and outcomes between both groups. Negative microbiology was found in 82 patients (30%). Both groups had similar baseline severity scores. Patients with negative microbiology presented more frequently chronic renal failure (15 [18%] vs 11 [6%]; p=0.003), chronic heart disorders (35 [43%] vs 55 [29%]; p=0.044), less frequently previous intubation (44 [54%] vs 135 [72%]; p=0.006), more severe hypoxemia (PaO2/FIO2: 165±73 mm Hg vs 199±79 mm Hg; p=0.001), and shorter ICU stay before the onset of pneumonia (5±5 days vs 7±9 days; p=0.001) compared with patients with positive microbiology. The systemic inflammatory response was similar between both groups. Negative microbiology resulted in less changes of empiric treatment (33 [40%] vs 112 [60%]; p=0.005) and shorter total duration of antimicrobials (13±6 days vs 17±12 days; p=0.006) than positive microbiology. Following adjustment for potential confounders, patients with positive microbiology had higher hospital mortality (adjusted odds ratio 2.96, 95% confidence interval 1.24-7.04, p=0.014) and lower 90-day survival (adjusted hazard ratio 0.50, 95% confidence interval 0.27-0.94, p=0.031), with a nonsignificant lower 28-day survival.
Although the possible influence of previous intubation in mortality of both groups is not completely discarded, negative microbiologic findings in clinically suspected ICU-acquired pneumonia are associated with less frequent previous intubation, shorter duration of antimicrobial treatment, and better survival. Future studies should corroborate the presence of pneumonia in patients with suspected ICU-acquired pneumonia and negative microbiology.
目前尚不清楚重症加强治疗病房(ICU)获得性肺炎而未明确病因对患者预后的影响。本研究比较了微生物学确诊的 ICU 获得性肺炎患者与未确诊的 ICU 获得性肺炎患者的临床特征、炎症反应和结局。
前瞻性观察性研究。
一所大学教学医院的 ICU。
前瞻性连续收集了 270 例 ICU 获得性肺炎患者。根据微生物学阳性或阴性结果将患者进行分组。
无。
比较了两组的特征和结局。82 例(30%)患者的微生物学结果为阴性。两组患者的基线严重程度评分相似。微生物学阴性组患者更常患有慢性肾衰竭(15 例[18%]比 11 例[6%];p=0.003)、慢性心脏疾病(35 例[43%]比 55 例[29%];p=0.044),较少接受过先前的插管(44 例[54%]比 135 例[72%];p=0.006),更严重的低氧血症(PaO2/FIO2:165±73mmHg 比 199±79mmHg;p=0.001),且在发生肺炎之前 ICU 住院时间更短(5±5 天比 7±9 天;p=0.001)。两组患者的全身炎症反应相似。与微生物学阳性组相比,微生物学阴性组的经验性治疗变化更小(33 例[40%]比 112 例[60%];p=0.005),抗菌药物总疗程更短(13±6 天比 17±12 天;p=0.006)。在校正了潜在混杂因素后,微生物学阳性组的住院死亡率更高(调整后优势比 2.96,95%置信区间 1.24-7.04,p=0.014),90 天生存率更低(调整后危险比 0.50,95%置信区间 0.27-0.94,p=0.031),28 天生存率虽较低,但无统计学意义。
尽管两组中先前插管的可能影响尚不完全排除,但在疑似 ICU 获得性肺炎的患者中发现微生物学阴性结果与较少的先前插管、较短的抗菌药物治疗时间和更好的生存有关。未来的研究应证实疑似 ICU 获得性肺炎且微生物学阴性的患者存在肺炎。